Axsome and Sandoz dismiss Sunosi patent litigation; Sandoz withdraws generic ANDA

Axsome Therapeutics, Inc.

Sandoz withdrew its ANDA for a generic equivalent of Sunosi (solriamfetol), leading to dismissal of patent litigation without prejudice.
Litigation was pending in U.S. District Court for the District of New Jersey.
Dismissal removes a potential near-term generic threat to Sunosi, Axsome's CNS product.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.